Key clinical point: There are no current guidelines for gastric cancer screening.
Major finding: The incremental cost-effectiveness ratio was lowest for Chinese, Japanese, and Korean Americans, all with values below $73,748 per quality-adjusted life-year.
Study details: Computer model with output compared with the Surveillance, Epidemiology, and End Results database.
Disclosures: The study was supported by the Agency for Healthcare Research and Quality, Patient-Centered Outcomes Research Institute, the American Gastroenterological Association, and the Department of Veteran Affairs.
Shah SC et al. Clin Gastroenterol Hepatol. 2020 July 21. doi: 10.1016/j.cgh.2020.07.031